Last SFr.106.50 CHF
Change Today +1.40 / 1.33%
Volume 53.0K
BSLN On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/12/14 - SFr.129.80
52 Week Low
10/16/14 - SFr.79.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, an integrated biopharmaceutical company, focuses on the discovery and development of pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology in Switzerland and China. The company markets Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids. It is also developing Isavuconazole, a Phase III development antifungal drug for the treatment of invasive fungal infections; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia, which is under regulatory review. In addition, the company is developing BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase I clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

200 Employees
Last Reported Date: 02/6/14
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.888.4K
Compensation as of Fiscal Year 2013.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica AG - Special Call

To discuss approval of FDA's Anti-Infective Drugs Advisory Committee on isavuconazole for the treatment of invasive aspergillosis and mucormycosis

Basilea Pharmaceutica Ltd. Announces FDA's Anti-Infective Drugs Advisory Committee Recommends Approval of Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis

Basilea Pharmaceutica Ltd. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted unanimously to recommend approval of the investigational once-daily intravenous and oral antifungal isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, for the treatment of invasive aspergillosis, and eight to two with one abstention to recommend approval for the treatment of invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.

Swissmedic Approves Basilea's Antibiotic Zevtera(R) (Ceftobiprole Medocaril) for the Treatment of Pneumonia

Basilea Pharmaceutica Ltd. reported that the Swiss regulatory authority Swissmedic has approved the antibiotic Zevtera® (ceftobiprole medocaril) for the treatment in adults of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). The license will be issued by Swissmedic following formal publication of the Product Information. Ceftobiprole for the treatment of pneumonia has already been approved in twelve other European countries.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.106.50 CHF +1.40

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.1x
Price/Book 14.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at